Conference Menu
Current Event OverviewMain ConferenceShort CoursesRegister PDF Download Posters Hotel & Travel Sponsor Press Pass Request Brochure Archives
Current Event
OverviewMain ConferenceShort CoursesRegister PDF Download Posters Hotel & Travel Sponsor Press Pass Request Brochure Archives
Highlights of Conference Presentations DVD
Circulating Tumor Cells: Assay Development and Clinical Utility DVD
Corporate Sponsors:
Corporate Support Sponsors:
Lead Publications:
Media Partners
Day 1 | Day 2 | Day 3
Monday, January 31, 2011
Main Conference
12:00 -1:45 pm Main Conference Registration
1:45 Welcoming Remarks
Tanuja Koppal, Ph.D., Conference Director
CHALLENGES IN PRE-CLINICAL TO CLINICAL TRANSLATION
1:50 Chairperson’s Opening Remarks
William Mattes, Ph.D., Principal Consultant, PharmPoint Consulting
2:00 Pre-Clinical Hepatotoxicity Biomarker Discovery
William Salminen, Ph.D., DABT, Director of the Center for Hepatotoxicity, U.S. FDA National Center for Toxicological Research
This presentation will provide an overview of a multiple -omics (genomics, proteomics, and metabolomics) approach being applied at the US FDA NCTR to facilitate the identification of idiosyncratic hepatotoxicants. It is hypothesized that by using more sensitive multiple -omics endpoints, biomarkers will be identified that allow better prediction of idiosyncratic hepatotoxicants in pre-clinical species. The results from this study will be published in the public domain to facilitate the identification of new biomarkers.
2:30 Alzheimer's Disease Biomarkers: Impact from Drug Discovery through Phase III
Mary J. Savage, Ph.D., Research Fellow, Molecular Biomarkers, Merck & Co.
The amyloid peptide biomarker has advanced several drug discovery targets including secretase inhibitors and immunotherapy approaches into clinical trials. This peptide manifests in several forms, both monomer and multimer and the nature of the toxic species is still not fully understood, nor is the mechanism by which it participates in the etiology of Alzheimer's Disease. Several clinical trials have initiated and some have stopped, affecting this biomarker to varying degrees. Data will be presented to describe some pitfalls in using the amyloid peptide as a biomarker to measure either acute drug responses or as a surrogate for efficacy in the clinic. The evolution of this peptide measure as a prognostic marker will also be discussed.
3:00 Networking Refreshment Break with Exhibit and Poster Viewing
3:30 FEATURED PRESENTATION
Safety Biomarkers in Action: Pre-Clinical to Clinical Translation
Calvert Louden, M.D., Senior Director of Pathology, Johnson & Johnson Pharmaceuticals
In toxicology (safety) the paradigm of mechanisms, models and markers is relevant to both safety and efficacy. However, the challenges for safety are significant and there is a strong emphasis to develop and employ new Safety Biomarkers (SBM). These new SBMs could contribute significantly to these challenges and be more informative if they can (1) distinguish between adaptive and toxic response (injury); (2) be predictive as well as diagnostic for injury that is minimal, progressive or reversible; (3) influence the selection of monitorable safety biomarkers for Phase 1 and beyond; (4) provide insights into the possible mode of action/mechanism of toxicity.
4:30 BREAKOUT DISCUSSIONS
Topic 1: To be Announced
Moderator: Calvert Louden, M.D., Johnson & Johnson Pharmaceuticals
Topic 2: Mass Spectrometry-based Biomarker Assays in the CLinical Lab: Pro or Con
Moderator: Samir Hanash, M.D., Ph.D., Fred Hutchinson Cancer Research Center
Topic 3: Quantifying and Validating Biomarkers in Biofluids that Lack ENdogenous Controls
Moderator: William Salminen, Ph.D., DABT, U.S. FDA National Center for Toxicological Research
Topic 4: Biomarker Uses: Internal Decision-Making Only, or for Regulatory Use?
Topic 5: Biomarkers for Development of Biologics
Moderator: Thomas Bocan, Ph.D., Senior Director, Head of BioImaging Center, Pfizer, Inc.
5:30 Opening Reception with Exhibit and Poster Viewing
6:30 pm End of Day One